PF-04523655: Completed Phase II enrollment

Quark said Pfizer completed enrollment in a single-blind Phase II trial evaluating PF-04523655 vs. laser therapy. The compound uses AtuRNAi chemistry from Silence Therapeutics plc (LSE:SLN, London, U...